Pricing Log in Create free account

Halozyme Therapeutics, Inc. (HALO) vs Jazz Pharmaceuticals PLC (JAZZ)

Halozyme Therapeutics, Inc. and Jazz Pharmaceuticals PLC are both Biotechnology companies. Halozyme Therapeutics, Inc. and Jazz Pharmaceuticals PLC are of similar size ($14.6B and $14.0B). Halozyme Therapeutics, Inc. trades at the lower P/E: 29.5× against 62.6×. Halozyme Therapeutics, Inc. grew revenue faster over the last twelve months: 45.0% against 13.5%. Halozyme Therapeutics, Inc. has the higher net margin (26.9% vs 4.37%) and the higher return on invested capital (19.9% vs 3.86%). Across the 21 metrics below, Halozyme Therapeutics, Inc. leads on 17 and Jazz Pharmaceuticals PLC on 4.

Valuation

Metric HALO JAZZ Biotechnology median
P/E 29.50 62.55 10.26
P/S 7.82 3.12 9.18
P/B n/m 3.51 2.05
Price to free cash flow 15.91 22.16 24.81
EV/EBITDA 22.63 15.24 0.65
EV/Sales 9.03 3.70 8.98
Earnings yield 3.39% 1.60% (34.89%)
Free cash flow yield 6.28% 4.51% (24.52%)

Profitability

Metric HALO JAZZ Biotechnology median
Gross margin 82.27% 89.09% 65.16%
Operating margin 37.41% 9.03% 0.00%
Net margin 26.93% 4.37% 0.00%
Free cash flow margin 49.84% 14.08% 0.00%
Return on equity 216.38% 5.05% (50.12%)
Return on assets 17.05% 1.76% (45.60%)
Return on invested capital 19.87% 3.86% 0.00%

Growth

Metric HALO JAZZ Biotechnology median
Revenue growth (TTM) 45.03% 13.48% 6.26%
EPS growth (last fiscal year) (25.36%) (167.51%) 29.88%
Revenue growth, 5-year CAGR 39.16% 12.54% 9.75%
Net income growth, 5-year CAGR 19.68% 0.00% 0.00%

Health

Metric HALO JAZZ Biotechnology median
Debt to equity (58.84) 1.33 0.00
Current ratio 3.88 1.82 4.89
Net debt to EBITDA 3.56 10.96 1.01

Dividend

Metric HALO JAZZ Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric HALO JAZZ Biotechnology median
Market cap 13.96b 14.59b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack